Who should pay for the continuity of post-trial health care treatments?

BACKGROUND: The bioethical debate in the world on who should pay for the continuity of post-trials treatment of patients that have medical indication remains obscure and introduces uncertainties to the patients involved in the trials. The continuity of post-trial treatment was only incorporated in t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Equity Health
Main Authors: Iunes, Roberto, Uribe, Manuela Villar, Torres, Janet Bonilla, Garcia, Marina Morgado, Alvares-Teodoro, Juliana, de Assis Acurcio, Francisco, Junior, Augusto Afonso Guerra
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6545625/
https://ncbi.nlm.nih.gov/pubmed/31155007
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12939-019-0919-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados